Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Kawasaki disease

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    Query did not match any clinical trials.
    These are paediatric studies completed by 26 January 2007, in respect of products authorised in the Community (Article 45 of the Paediatric Regulation (EC) No 1901/2006).
    Note: Advanced search filters for country, trial phase, gender, rare disease, IMP with orphan designation in the indication and age ranges of in-utero, adult or elderly do not apply to these records.
    1  2  Next»
    Study title: Kawasaki disease associated coronary artery lesions with navigator echo-based respiratory gated three dimensional coronary magnetic resonance angiography compared with achocardiography in young children;Amino M; J. Tokyo Med. Univ.; 2004 vol.62 n.2 p.146-152Kawasaki disease associated coronary artery lesions with navigator echo-based respiratory gated three dimensional coronary magnetic resonance angiography compared with achocardiography in young children;Amino M; J. Tokyo Med. Univ.; 2004 vol.62 n.2 p.146-152
    Active substance: GADOTERIC ACID
    Study summary document link (including results):
    View full study record
    Document reference: 28864
    Study title: Unexpected myocardial uptake on bone scintigraphy in an infant with Kawasaki disease. Macdonald WB, Troedson RG. Clin Nucl Med. 2001 May;26(5):455. No abstract available.
    Active substance: TECHNETIUM (99mTc) MEDRONIC ACID
    Study summary document link (including results):
    View full study record
    Document reference: 43454
    Study title: Usefulness of Tc-99m HMPAO-labeled WBC heart scan to predict impaired ventricular function and coronary artery dilation in children with Kawasaki diseaseHsiu-Bao Hsua, Yun-Ching Fub,c,*, Shih-Chuan Tsaid, Ruoh-Fang Yene, Betau Hwangc,f. International Journal of Cardiology 92 (2003) 65– 69
    Active substance: CERETEC
    Study summary document link (including results): hsiu-bao h 2003.pdf
    View full study record
    Document reference: 48591
    Study title: Am J Cardiol. 1996 Jul 15;78(2):175-81. Evaluation of myocardial ischemia and infarction by signal-averaged electrocardiographic late potentials in children with Kawasaki disease. Ogawa S, Nagai Y, Zhang J, Yuge K, Hino Y, Jimbo O, Fukazawa R, Hayashi RAm J Cardiol. 1996 Jul 15;78(2):175-81. Evaluation of myocardial ischemia and infarction by signal-averaged electrocardiographic late potentials in children with Kawasaki disease. Ogawa S, Nagai Y, Zhang J, Yuge K, Hino Y, Jimbo O, Fukazawa R, Hayashi R
    Active substance: THALLIUM 201T1 CHLORIDE
    Study summary document link (including results):
    View full study record
    Document reference: 44508
    Study title: Pharmacokinetic and tolerability assessment of a pediatric oral formulation of pentoxifylline in Kawasaki disease. Current-Ther-research,64;2:96-115 - Best-Brookie - February 2003 - Publication in NDA Annual Report -Pharmacokinetic and tolerability assessment of a pediatric oral formulation of pentoxifylline in Kawasaki disease. Current-Ther-research,64;2:96-115 - Best-Brookie - February 2003 - Publication in NDA Annual Report -
    Active substance: PENTOXYFILLINE
    Study summary document link (including results):
    View full study record
    Document reference: 45846
    Study title: J Cardiogr. 1981 Mar;11(1):105-14. [Myocardial imaging with thallium -201 in the patients with coronary involvement after Kawasaki disease (author's transl)] [Article in Japanese] J Cardiogr. 1981 Mar;11(1):105-14. [Myocardial imaging with thallium -201 in the patients with coronary involvement after Kawasaki disease (author's transl)] [Article in Japanese]
    Active substance: THALLIUM 201T1 CHLORIDE
    Study summary document link (including results):
    View full study record
    Document reference: 44593
    Study title: Tokai J Exp Clin Med. 1982 Jan;7(1):69-75. Thallium--201 myocardial imaging in Kawasaki disease. Kato S, Ohta T, Suzuki Y, Matsuyama S. Tokai J Exp Clin Med. 1982 Jan;7(1):69-75. Thallium--201 myocardial imaging in Kawasaki disease. Kato S, Ohta T, Suzuki Y, Matsuyama S.
    Active substance: THALLIUM 201T1 CHLORIDE
    Study summary document link (including results):
    View full study record
    Document reference: 44710
    Study title: Am Heart J. 1988 Dec;116(6 Pt 1):1575-9. Dipyridamole-thallium-201 tomography documenting improved myocardial perfusion with therapy in Kawasaki disease. Nienaber CA, Spielmann RP, Hausdorf G Am Heart J. 1988 Dec;116(6 Pt 1):1575-9. Dipyridamole-thallium-201 tomography documenting improved myocardial perfusion with therapy in Kawasaki disease. Nienaber CA, Spielmann RP, Hausdorf G
    Active substance: THALLIUM 201T1 CHLORIDE
    Study summary document link (including results):
    View full study record
    Document reference: 44497
    Study title: Am Heart J. 1988 Oct;116(4):1028-33. ECG findings after myocardial infarction in children after Kawasaki disease. Nakanishi T, Takao A, Kondoh C, Nakazawa M, Hiroe M, Matsumoto Y. Am Heart J. 1988 Oct;116(4):1028-33. ECG findings after myocardial infarction in children after Kawasaki disease. Nakanishi T, Takao A, Kondoh C, Nakazawa M, Hiroe M, Matsumoto Y.
    Active substance: THALLIUM 201T1 CHLORIDE
    Study summary document link (including results):
    View full study record
    Document reference: 44498
    Study title: Nippon Kyobu Geka Gakkai Zasshi. 1989 Jan;37(1):103-9. [Follow-up study of coronary artery bypass grafting after Kawasaki disease--early and late postoperative evaluation] [Article in Japanese] Ohara K, Yagihara T, Kishimoto H, Isobe F, Yamamoto F, NabNippon Kyobu Geka Gakkai Zasshi. 1989 Jan;37(1):103-9. [Follow-up study of coronary artery bypass grafting after Kawasaki disease--early and late postoperative evaluation] [Article in Japanese] Ohara K, Yagihara T, Kishimoto H, Isobe F, Yamamoto F, Nab
    Active substance: THALLIUM 201T1 CHLORIDE
    Study summary document link (including results):
    View full study record
    Document reference: 44671
    Study title: Am Heart J. 1998 Mar;135(3):482-7. Noninvasive evaluation of myocardial ischemia in Kawasaki disease: comparison between dipyridamole stress thallium imaging and exercise stress testing. Fukuda T, Akagi T, Ishibashi M, Inoue O, Sugimura T, Kato H. Am Heart J. 1998 Mar;135(3):482-7. Noninvasive evaluation of myocardial ischemia in Kawasaki disease: comparison between dipyridamole stress thallium imaging and exercise stress testing. Fukuda T, Akagi T, Ishibashi M, Inoue O, Sugimura T, Kato H.
    Active substance: THALLIUM 201T1 CHLORIDE
    Study summary document link (including results):
    View full study record
    Document reference: 44499
    Study title: Circ J. 2002 Jan;66(1):63-9. Dobutamine stress radionuclide ventriculography reveals silent myocardial dysfunction in Kawasaki disease. Hamamichi Y, Ichida F, Tsubata S, Hirono K, Watanabe S, Rui C, Yu X, Uese K, Hashimoto I, Simizu M, Seto H, Origasa HCirc J. 2002 Jan;66(1):63-9. Dobutamine stress radionuclide ventriculography reveals silent myocardial dysfunction in Kawasaki disease. Hamamichi Y, Ichida F, Tsubata S, Hirono K, Watanabe S, Rui C, Yu X, Uese K, Hashimoto I, Simizu M, Seto H, Origasa H
    Active substance: THALLIUM 201T1 CHLORIDE
    Study summary document link (including results):
    View full study record
    Document reference: 44533
    Study title: Pediatr Cardiol. 1991 Apr;12(2):78-82. Asymptomatic myocardial infarction in Kawasaki disease: long-term prognosis. Shiraishi I, Onouchi Z, Hayano T, Hamaoka K, Kiyosawa N. Pediatr Cardiol. 1991 Apr;12(2):78-82. Asymptomatic myocardial infarction in Kawasaki disease: long-term prognosis. Shiraishi I, Onouchi Z, Hayano T, Hamaoka K, Kiyosawa N.
    Active substance: THALLIUM 201T1 CHLORIDE
    Study summary document link (including results):
    View full study record
    Document reference: 44678
    Study title: Pediatr Cardiol. 1993 Mar;14(2):67-74. Discordance between thallium-201 scintigraphy and coronary angiography in patients with Kawasaki disease: myocardial ischemia with normal coronary angiogram. Fukazawa M, Fukushige J, Takeuchi T, Narabayashi Pediatr Cardiol. 1993 Mar;14(2):67-74. Discordance between thallium-201 scintigraphy and coronary angiography in patients with Kawasaki disease: myocardial ischemia with normal coronary angiogram. Fukazawa M, Fukushige J, Takeuchi T, Narabayashi
    Active substance: THALLIUM 201T1 CHLORIDE
    Study summary document link (including results):
    View full study record
    Document reference: 44679
    Study title: Pediatr Cardiol. 1996 Mar-Apr;17(2):71-6. Long-term outcome of coronary abnormalities in patients after Kawasaki disease. Fukushige J, Takahashi N, Ueda K, Hijii T, Igarashi H, Ohshima A. Pediatr Cardiol. 1996 Mar-Apr;17(2):71-6. Long-term outcome of coronary abnormalities in patients after Kawasaki disease. Fukushige J, Takahashi N, Ueda K, Hijii T, Igarashi H, Ohshima A.
    Active substance: THALLIUM 201T1 CHLORIDE
    Study summary document link (including results):
    View full study record
    Document reference: 44680
    Study title: J Pediatr. 1990 Jan;116(1):52-6. Myocardial performance and perfusion during exercise in patients with coronary artery disease caused by Kawasaki disease. Paridon SM, Ross RD, Kuhns LR, Pinsky WW. J Pediatr. 1990 Jan;116(1):52-6. Myocardial performance and perfusion during exercise in patients with coronary artery disease caused by Kawasaki disease. Paridon SM, Ross RD, Kuhns LR, Pinsky WW.
    Active substance: THALLIUM 201T1 CHLORIDE
    Study summary document link (including results):
    View full study record
    Document reference: 44626
    Study title: Kurume Med J. 1992;39(4):245-55. Myocardial ischemia in Kawasaki disease; evaluation by dipyridamole stress thallium-201 (Tl-201) myocardial imaging and exercise stress test. Fukuda T. Kurume Med J. 1992;39(4):245-55. Myocardial ischemia in Kawasaki disease; evaluation by dipyridamole stress thallium-201 (Tl-201) myocardial imaging and exercise stress test. Fukuda T.
    Active substance: THALLIUM 201T1 CHLORIDE
    Study summary document link (including results):
    View full study record
    Document reference: 44660
    Study title: J Cardiogr. 1982 Jun;12(2):387-99. [Myocardial imaging in patients with Kawasaki disease: exercise stress imaging and serial studies] [Article in Japanese] Ono Y, Tanimoto T, Kijima Y, Kohata T, Suzuki A, Kamiya T, Nishimura T, Kozuka T. J Cardiogr. 1982 Jun;12(2):387-99. [Myocardial imaging in patients with Kawasaki disease: exercise stress imaging and serial studies] [Article in Japanese] Ono Y, Tanimoto T, Kijima Y, Kohata T, Suzuki A, Kamiya T, Nishimura T, Kozuka T.
    Active substance: THALLIUM 201T1 CHLORIDE
    Study summary document link (including results):
    View full study record
    Document reference: 44595
    Study title: J Cardiogr. 1984 Jun;14(1):59-73. [Diagnosis of myocardial ischemia in Kawasaki disease: thallium-201 myocardial imagings at rest, with exercise and with dipyridamole administration] [Article in Japanese] Mitomori T, Ono Y, Sugiyama H, Suzuki A, KamiyaJ Cardiogr. 1984 Jun;14(1):59-73. [Diagnosis of myocardial ischemia in Kawasaki disease: thallium-201 myocardial imagings at rest, with exercise and with dipyridamole administration] [Article in Japanese] Mitomori T, Ono Y, Sugiyama H, Suzuki A, Kamiya
    Active substance: THALLIUM 201T1 CHLORIDE
    Study summary document link (including results):
    View full study record
    Document reference: 44596
    Study title: Clin Nucl Med. 1992 Mar;17(3):191-4. Noninvasive assessment of myocardium at risk by Tl-201 SPECT imaging in a child with Kawasaki disease. A case report. Civelek AC, Kavanaugh-McHugh A, Ozguven MA, Durski K, Camargo EE. Clin Nucl Med. 1992 Mar;17(3):191-4. Noninvasive assessment of myocardium at risk by Tl-201 SPECT imaging in a child with Kawasaki disease. A case report. Civelek AC, Kavanaugh-McHugh A, Ozguven MA, Durski K, Camargo EE.
    Active substance: THALLIUM 201T1 CHLORIDE
    Study summary document link (including results):
    View full study record
    Document reference: 44549
    1  2  Next»
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 02 21:18:46 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA